Last reviewed · How we verify
Placebo (for allopurinol)
Placebo (for allopurinol) is a Small molecule drug developed by University of Dundee. It is currently FDA-approved for Control arm in allopurinol efficacy trials (not a therapeutic indication). Also known as: Placebo.
A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and psychophysiological processes.
A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and psychophysiological processes. Used for Control arm in allopurinol efficacy trials (not a therapeutic indication).
At a glance
| Generic name | Placebo (for allopurinol) |
|---|---|
| Also known as | Placebo |
| Sponsor | University of Dundee |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Gout |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to measure the effect of expectation, belief, and the therapeutic context independent of the drug's active ingredient. In this case, it serves as a control comparator in trials evaluating allopurinol's efficacy for urate-lowering therapy. Any observed benefit reflects placebo response rather than direct molecular action.
Approved indications
- Control arm in allopurinol efficacy trials (not a therapeutic indication)
Common side effects
Key clinical trials
- Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT (NA)
- Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout (PHASE2, PHASE3)
- Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (PHASE3)
- Effect of Allopurinol on Markers of Mineral and Bone Metabolism (NA)
- A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout (PHASE3)
- The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk (PHASE3)
- The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More (PHASE4)
- Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for allopurinol) CI brief — competitive landscape report
- Placebo (for allopurinol) updates RSS · CI watch RSS
- University of Dundee portfolio CI
Frequently asked questions about Placebo (for allopurinol)
What is Placebo (for allopurinol)?
How does Placebo (for allopurinol) work?
What is Placebo (for allopurinol) used for?
Who makes Placebo (for allopurinol)?
Is Placebo (for allopurinol) also known as anything else?
What development phase is Placebo (for allopurinol) in?
Related
- Manufacturer: University of Dundee — full pipeline
- Therapeutic area: All drugs in Rheumatology / Gout
- Indication: Drugs for Control arm in allopurinol efficacy trials (not a therapeutic indication)
- Also known as: Placebo